Celularity (NASDAQ:CELU - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Thursday.
Celularity Stock Performance
CELU traded down $0.20 during mid-day trading on Thursday, reaching $2.29. 78,022 shares of the stock were exchanged, compared to its average volume of 334,717. The stock has a market capitalization of $54.84 million, a PE ratio of -0.86 and a beta of 0.61. The company has a 50 day moving average price of $1.73 and a two-hundred day moving average price of $2.01. Celularity has a 1 year low of $1.00 and a 1 year high of $5.22.
Celularity (NASDAQ:CELU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($1.50) by $0.91. The company had revenue of $18.13 million for the quarter, compared to analysts' expectations of $5.20 million. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%.
Institutional Investors Weigh In On Celularity
Hedge funds have recently made changes to their positions in the business. Keynote Financial Services LLC raised its stake in shares of Celularity by 90.1% during the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company's stock worth $52,000 after purchasing an additional 11,863 shares during the period. C V Starr & Co. Inc. bought a new stake in shares of Celularity during the 4th quarter worth $1,589,000. Biltmore Family Office LLC bought a new stake in shares of Celularity during the 4th quarter worth $73,000. Acadian Asset Management LLC bought a new stake in shares of Celularity during the 1st quarter worth $34,000. Finally, Two Sigma Investments LP bought a new stake in shares of Celularity during the 4th quarter worth $93,000. 19.02% of the stock is currently owned by institutional investors.
Celularity Company Profile
(
Get Free Report)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Further Reading
Before you consider Celularity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celularity wasn't on the list.
While Celularity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
